Abstract: Lung diseases, such as pulmonary hypertension and pulmonary fibrosis, are life-threatening diseases and have common features of vascular remodeling. During progression, extracellular matrix protein deposition and dysregulation of proteolytic enzymes occurs, which results in vascular stiffness and dysfunction. Although vasodilators or anti-fibrotic therapy have been mainly used as therapy owing to these characteristics, their effectiveness does not meet expectations. Therefore, a better understanding of the etiology and new therapeutic approaches are needed. Endothelial cells (ECs) line the inner walls of blood vessels and maintain vascular homeostasis by protecting vascular cells from pathological stimuli. Chronic stimulation of ECs by various factors, including pro-inflammatory cytokines and hypoxia, leads to ECs undergoing an imbalance of endothelial homeostasis, which results in endothelial dysfunction and is closely associated with vascular diseases. Emerging studies suggest that endothelial to mesenchymal transition (EndMT) contributes to endothelial dysfunction and plays a key role in the pathogenesis of vascular diseases. EndMT is a process by which ECs lose their markers and show mesenchymal-like morphological changes, and gain mesenchymal cell markers. Despite the efforts to elucidate these molecular mechanisms, the role of EndMT in the pathogenesis of lung disease still requires further investigation. Here, we review the importance of EndMT in the pathogenesis of pulmonary vascular diseases and discuss various signaling pathways and mediators involved in the EndMT process. Furthermore, we will provide insight into the therapeutic potential of targeting EndMT.

Keywords: lung disease; endothelial to mesenchymal transition; pulmonary hypertension; pulmonary fibrosis
of mesenchymal markers, such as fibronectin, alpha-smooth muscle actin (SMAα), smooth muscle protein 22 alpha, vimentin, and neural cadherin (N-cadherin), are upregulated [7,8]. The morphology of ECs undergoing EndMT changes from a cobblestone monolayer to an elongated phenotype [9]. This phenomenon mainly occurs during embryonic cardiac development, but is also involved in various lung diseases, such as pulmonary arterial hypertension (PAH) and pulmonary fibrosis (PF) (Figure 1) [7,10–13].

![Figure 1](image_url)  
**Figure 1.** A schematic representation of endothelial-to-mesenchymal transition (EndMT) involved in lung diseases. Endothelial cells stimulated by transforming growth factor-β (TGFβ), interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and hypoxia undergo EndMT. EndMT is characterized by phenotypic change from a cobblestone into an elongated shape, loss of endothelial markers, and the acquisition of mesenchymal markers. EndMT contributes to the pathogenesis of lung diseases, including pulmonary arterial hypertension (PAH), radiation-induced pulmonary fibrosis (RIPF), and idiopathic pulmonary fibrosis (IPF). Various mediators and transcription factors are identified in this process.
Pulmonary hypertension (PH) is categorized into five groups: PAH, PH due to left heart disease, PH due to lung diseases and/or hypoxia, PH due to pulmonary arterial obstructions, and PH with unclear and/or multifactorial mechanisms [14–16]. PAH has been defined as pulmonary artery pressure (PAP) ≥ 25 mmHg at rest and occurs as a result of multiple causes, such as heritable factors (mainly bone morphogenic protein receptor-2 (BMPR2) mutations), drugs and toxins, as well as association with other diseases; however, PAH without known causes is known as idiopathic PAH (IPAH) [14,17]. Vascular remodeling in PAH is characterized by the aberrant proliferation of pulmonary arterial ECs (PAECs) and smooth muscle cells (SMCs), which form occlusive neointima and vascular structural changes [18–20]. These progressive changes cause excess vasoconstriction and right ventricle hypertrophy and, ultimately, death [18–20]. Endothelial dysfunction is a key player in the pathogenesis of PAH [21]. Growing evidence suggests that EndMT potentially contributes to endothelial dysfunction and the vascular remodeling of PAH [7,11,22,23]. Indeed, many studies have demonstrated that various signaling pathways and mediators, including transforming growth factor beta (TGFβ), nuclear factor kappa B (NF-κB), Notch, and microRNA, are involved in the EndMT of PAH [24,25]. It has been reported that the endothelial-specific loss of BMPR2, known as the principal mutation factor of heritable PAH, induces EndMT in vitro and in vivo [7,11,23]. In addition, exposure to hypoxia or chronic stimulation with proinflammatory cytokines or TGFβ also induce EndMT in vitro and in vivo [26–30]. However, the contribution of EndMT to disease progression is not fully understood [2]. Current therapies for PAH, such as phosphodiesterase-5 inhibitors, prostacyclin analogues, and endothelin receptor antagonists, can help relieve symptoms and slow progression, but there is no effective treatment [21,31]. Thus, targeting EndMT is emerging as a novel therapeutic approach by alleviating vascular remodeling and the PAH phenotype in vitro and in vivo [7,29,32–36].

Idiopathic PF (IPF) is chronic, progressive, and the most common interstitial lung disease without a definite etiology [37,38]. Various cell types, such as epithelial cells, pneumocytes, ECs, pericytes, fibrocytes, resident fibroblasts, and mesenchymal cells, are associated with the pathogenesis of IPF [25]. The injured epithelial cells, through aging, genetic susceptibility and repetitive microinjury, release fibrogenic factors and cytokines, resulting in the recruitment of contractile myofibroblasts, which are key cellular mediators of fibrosis [38]. Recruited myofibroblasts undergoing activation and proliferation induce extracellular matrix expansion, which consequently results in aberrant vascular remodeling in the lung [38]. The myofibroblasts are derived not only from the proliferation of resident mesenchymal cells, circulating fibrocytes, lung interstitium pericytes, epithelial–mesenchymal transition, but also EndMT. [38–40]. Many studies have demonstrated that EndMT occurs in the lung tissue of IPF patients and animal models, suggesting EndMT may play an important role in pathological processes in PF [25,41,42]. In addition, emerging evidence indicates that inhibiting EndMT can also be a therapeutic strategy in PF in vivo [41,43–45].

This review highlights the role of EndMT associated with pulmonary diseases, such as PAH and PF. Moreover, this review discusses molecular mechanisms, epigenetic modulation, and recent clinical relevance in lung diseases.

2. EndMT in Pulmonary Hypertension

PH is characterized by the muscularization of arterioles, medial thickening, plexiform region formation, intimal fibrosis, and the hyperproliferation of ECs and SMCs [15,16,46,47]. Most studies have identified EndMT by analyzing the co-expression of endothelial markers and mesenchymal markers in the lung tissue of patients and experimental PH animal models. EndMT has been observed in pathological lesions in the lungs of PH patients [7,30,32,48,49]. Endothelial (CD31, CD34, and VE-cadherin) and mesenchymal marker (SMAα) double-positive cells were observed in intimal and plexiform lesions in the lung tissue of PAH patients [7]. Another group also demonstrated that neointimal and plexiform lesions in the lung tissue of human PAH patients contain endothelial markers, CD31 or von Willebrand factor (vWF), and SMAα co-expressing cells [48]. Isobe et al. reported that the CD44 spliced variant form (CD44v) results from EndMT, and its positive cells also...
expressed vWF and SMAα in neointimal lesions of IPAH patients [32]. The 4 ± 1% of pulmonary arterioles in systemic sclerosis (SSc)-PAH patients showed vWF/SMAα co-localization [30]. CD31 and SMAα co-expressing cells were detected in endarterectomized tissues from patients with chronic thromboembolic pulmonary hypertension (CTEPH) [49].

In addition to performing the double staining of endothelial and mesenchymal markers, ECs isolated from the lung have also been used for studying EndMT [49,50]. Endothelial-like cells isolated from the vascular tissue of patients with CTEPH underwent disruption of the endothelial monolayer and abnormal growth even after sorting with CD31 [49]. In addition, conditioned media from myofibroblast-like cells isolated from CTEPH patients induced phenotypic changes and mesenchymal marker expression in pulmonary microvascular ECs (PMVECs) [49]. Pulmonary vascular ECs (PVECs) isolated from patients with IPAH exhibited molecular characteristics of EndMT and a spindle-shaped morphology, which was similar to that of normal PVECs treated with TGFβ1, a well-known factor of EndMT [50]. Pulmonary arteries isolated from PAH patients showed increased mRNA levels of mesenchymal markers and EndMT-related factors, which also supports EndMT [7].

Animal models have also been used to demonstrate EndMT. Monocrotaline (MCT) injection causes endothelial injury and pulmonary vascular remodeling, and is commonly used to induce severe PH [50,51]. Several groups observed the reduction of endothelial markers and the induction of mesenchymal markers, as well as the co-staining of SMAα and endothelial marker (CD31 or CD34), in the lung tissue of MCT-induced PH rats [7,28,29,50,52]. Zhang et al. found that changes in endothelial and mesenchymal cell marker expressions occurred in a time-dependent manner during MCT-induced PAH development [51]. Chronic hypoxia also contributes to the vascular remodeling of small pulmonary arteries [27,53]. With this, it has been demonstrated that three weeks of hypoxia induces EndMT in the pulmonary arteries of rats and mice [26,53]. EndMT was further identified within the intimal layer of small pulmonary arteries, but not in large arteries, in chronic hypoxia-induced PH rats [27]. The combination of SU5416, a vascular endothelial growth factor receptor antagonist, and a chronic hypoxia model (SuHx) has been used for severe PH owing to the similarity of pathological lesions to plexiform lesions of human PAH [53]. In the lung of the SuHx model that had over 80 mmHg of right ventricular systolic pressure (RVSP), transitions of vWF+ vimentin− ECs to vWF− vimentin high mesenchymal-like cells were observed in pulmonary vascular lesions [7]. Tie2+ vimentin+ and Tie2+ SMAα+ cells were also found in occlusive lesions [7]. In addition, 6 ± 1% of pulmonary vessels had vWF/SMAα double-positive ECs, which contrasts with normal tissues having only 1% transitional EndMT cells in SuHx mice [30].

In general, endothelial and mesenchymal marker double-positive cells are considered EndMT-induced cells. However, this approach has the limitation of not being able to distinguish complete EndMT (cEndMT), where there are lost endothelial markers, and partial EndMT (pEndMT) cells. To overcome this problem, several studies have used endothelial-specific fluorescence transgenic animals [48,54]. Qiao et al. established VE-cadherin Cre or Tie2 Cre-mTomato/mGFP lineage-tracing mice [48]. Histological analysis identified SMAα-expressing neointima in an experimental PH animal model derived from the endothelium in VE-cadherin Cre or Tie2 Cre-mTomato/mGFP lineage-tracing mice [48]. Furthermore, cEndMT cells isolated from SuHx-induced Cdh5-Cre/CAG-GFP double-transgenic mice showed a spindle-like morphology and were characterized by mesenchymal-like functions, such as high proliferation and migration ability [54]. Additionally, conditioned media from cEndMT had a paracrine effect on the proliferation and migration of non-endothelial mesenchymal cells, suggesting that EndMT contributes directly and indirectly to the vascular remodeling of PAH [54].
3. EndMT in Pulmonary Fibrosis

IPF characterizes matrix deposition and fibrotic tissue remodeling, and it has been demonstrated that fibroblasts are involved in pathogenesis; thus, efforts to identify the origin of fibroblasts have been made. [42,55]. In the lung tissue of radiation-induced pulmonary fibrosis (RIPF) patients and radiation-exposed mouse models, the co-localization of CD31 and SMAα was significantly elevated compared to that of the control group, indicating EndMT [41]. The same group also reported endothelial heat shock protein beta 1 (HSPB1)-dependent EndMT in the PF of lung cancer [45]. The bleomycin-induced PF in animal models is the most commonly used model to study human IPF by causing damage to epithelial cells and alveolar inflammation [56,57]. Another group reported significant alterations of EC markers in the lungs of bleomycin-treated endothelial-specific autophagy-related 7 (ATG7) knockout mice compared to bleomycin-treated WT mice [58]. Hashimoto et al. established a Tie2-Cre/CAG-CAT-LacZ double transgenic mice model to track endothelial-derived fibroblasts in bleomycin-induced PF [42]. The 16.2% of lung fibroblasts isolated from bleomycin-treated mice were X-gal-staining-positive and 14.8% of X-gal-positive cells were SMAα- and Collagen I-double positive (myofiboblast), while the other 85.2% were SMAα-negative and Collagen I-positive, suggesting that a significant number of fibroblasts are EC-derived [42]. Suzuki et al. demonstrated that PVECs isolated from lipopolysaccharide (LPS)-induced mouse lungs undergo EndMT using the double staining of CD31 and SMAα or S100A4 [59]. Flow cytometry analysis showed that the number of SMAα+PVECs and S100A4+PVECs increased, while the total number of PVECs decreased [59].

Taken together, EndMT may play a key role in the pathogenesis of lung diseases. Many studies describe EndMT based on the evidence of co-expression of EC markers and mesenchymal markers in the lung tissue of animal disease models or human patients, which has a primary limitation because EndMT is a switching process; thus, the underlying molecular mechanisms are not yet fully understood. The methods to clarify partial and complete EndMT processes have been improved using endothelial-specific fluorescence transgenic mice; however, further investigation with human samples is needed. Thus, the clinical relevance of EndMT should be thoroughly assessed.

4. Key Signaling Pathways and Mediators during EndMT in Lung Diseases

The understanding of the key molecular mechanisms and mediators during EndMT is an important step toward finding how to develop EndMT inhibitors that can be applied to vascular disease therapy. Inflammatory stress contributes to endothelial dysfunction in the pathogenesis of lung diseases [2,60]. The combination of proinflammatory cytokines, including interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNFα), and TGFβ, is a powerful EndMT inducer [28–30,32,34]. Good et al. found that the combination of IL-1β, TNFα, and TGFβ1 for six days induces EndMT in PAECs (I-EndMT) [30]. I-EndMT PAECs and lung fibroblasts isolated from patients with SSc-PAH showed elevated levels of cytokines, such as IL-6, IL-8, IL-13, and TNFα [30]. In addition, a cocktail of IL-1β, TNFα, and TGFβ1 induces CD44v and EndMT in PAECs [32]. CD44v-positive EndMT-induced PAECs showed upregulations of proinflammatory cytokines and chemokines, such as TNFα, IL-1β, IL-6, and CXCL12 [32]. The combination of TGFβ1 and IL-1β induces EndMT through Smad2/3 and ERK1/2 phosphorylation, which means that both Smad and non-Smad signaling are involved in this process [28]. Moreover, it has been demonstrated that cytokine levels, such as TGFβ1, IL-1β, IL-6, and TNFα, are increased in the lung tissue of MCT-induced PH rats [28,29]. Therefore, inflammatory cytokines induce EndMT and also induce cells to exhibit proinflammatory characteristics.

Among the various signaling pathways involved in EndMT, TGFβ signaling is known to be a major regulator of EndMT [61]. TGFβ upregulates EndMT-associated transcription factors, such as Snail, Slug, and Twist1, which leads to the upregulation of mesenchymal markers [2,61]. Although TGFβ induces EndMT mainly through the Smad-dependent canonical signaling pathway, Smad-independent non-canonical TGFβ signaling is also involved [61]. Non-canonical TGFβ signaling includes phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and extracellular signal-regulated kinase (ERK) [62]. One group reported that ATG7 knockout
promotes EndMT in PAECs [58]. During this process, mRNA and protein levels of TGFβ1 and its receptors, TGFβR1 and TGFβR2, are increased, and this elevates the phosphorylation of Smad2/3, leading to the upregulation of Slug and pro-fibrotic genes, connective tissue growth factor, and Collagen I [58]. Sabbini and colleagues reported that the endothelial loss of Akt1 increased TGFβ2 expression, which in turn elevated the phosphorylation of p38-MAPK and Smad2/3, resulting in EndMT [53]. These results indicate that both canonical and non-canonical signaling pathways are involved in TGFβ2-induced EndMT [53]. In addition, the inhibitor of beta catenin (β-catenin) suppressed the expression of mesenchymal markers and ameliorated vascular thickening in a SuHx PH model, suggesting that Akt1-mediated β-catenin signaling is a novel pathway for inducing EndMT [53]. Caveolin-1 plays an important role in the internalization of the TGFβ receptor [63]. The expression levels of Snail, Slug, SMAα and Collagen I were higher in pulmonary ECs isolated from Caveolin-1 knockout mice than in WT mice [63]. Moreover, TGFβ1 treatment further increased SMAα and Collagen I expression in Caveolin-1 knockout cells [63]. The phosphorylated Twist1 and vimentin were elevated in the lungs of PAH patients and MCT-induced PH rats, and TGFβ treatment increases Twist1 expression [7,64]. Mammoto et al. reported that the overexpression of Twist1 induces EndMT through TGFβR2-Smad2 signaling, and the phosphorylation of Twist1 Ser42 is required during hypoxia-induced EndMT [65].

BMPR2 is a member of the TGF receptor superfamily and is highly expressed on the pulmonary vascular endothelium [36,66–68]. BMPR2 mutations and low expression levels are closely associated with PAH [36,66–69]. Roughly 70–80% of familial PAH and 10–20% of sporadic cases of IPAH patients have BMPR2 mutations [36,66]. Several studies have demonstrated that BMPR2 expression is associated with EndMT in the lung vasculature of PAH animal models and patients [7,23,50,54]. Dysfunction of BMPR2 signaling induces EndMT through high mobility group AT-hook 1 (HMGA1) upregulation [23]. The knockdown of HMGA1 or Slug prevented BMPR2 silencing-induced SMAα expression [23]. In addition, pulmonary ECs isolated from endothelial-specific BMPR2 knockout mice also showed EndMT with elevated HMGA1 and its target, Slug, expression [23]. BMPR2-deficient (BMPR2Δ140Ex1+/+) rats exhibit spontaneous pulmonary vascular remodeling [7]. A recent study reported that BMPR2 knockdown leads to the switch of cell junction protein from VE-cadherin to N-cadherin and increases Slug and Twist [11]. During this process, the heteromerization of BMP and TGFβ receptors was facilitated, leading to increased lateral TGFβ signaling responses [11]. Reynolds et al. reported that adenoviral BMPR2 delivery attenuates vascular remodeling in PAH animal models and treatment with BMPR2 ligands ameliorates TGFβ1-induced EndMT in vitro [36]. Accumulating evidence indicates that altered BMPR2 signaling is closely related to EndMT, and restoration of BMPR2 signaling can be a strategy for inhibiting EndMT.

Hypoxia contributes to EndMT in pulmonary ECs [26,27,70]. The hypoxia-inducible factor (HIF) family consists of HIF-1, HIF-2, and HIF-3, which are key regulators in maintaining oxygen homeostasis [50,71]. It has been reported that PVECs from PAH patients show EndMT with higher HIF-2α levels compared to control [50]. Although HIF-2α is degraded by prolyl hydroxylase domain protein 2 (PHD2) under normoxia, PHD2 was decreased in PVECs from IPAH, leading to the upregulation of Snail and Slug [50,71]. This suggests that PHD2 and HIF-2α are closely associated with EndMT. PHD2 endothelial-specific knockout mice showed a severe PH phenotype, even under normoxia, while endothelial-specific HIF-2α knockout mice prevented developing hypoxia-induced PH [50]. Hypoxia upregulates HIF-1α, which acts as an upstream regulator of Twist1 by binding to its promoter and leads to EndMT [27]. Choi et al. described that HIF-1α is elevated in EndMT-derived cells in the lung tissue of radiation-induced fibrosis mice and human RIPF patients [41]. In addition, this study demonstrated that HIF-1α mediates TGFβ receptor/Smad signaling in radiation-induced EndMT [41]. These studies reflect the critical role of the HIF family in hypoxia-induced EndMT.

Notch is a family of transmembrane receptors and consists of Notch 1, 2, 3, and 4 [72,73]. Notch is activated by ligands, Jagged 1, Jagged 2, and Delta-like 1, 3, and 4, and produces the intracellular domain of Notch by proteolytic processing [72,73]. Notch signaling pathways have been associated with epithelial-to-mesenchymal transition and EndMT [72–74]. Noseda et al. demonstrated that
activated Notch (Notch4IC, Notch1IC) and Jagged 1 lead to EndMT in human microvascular ECs [72]. Zhang et al. identified that Galectin-3 (Gal-3) is increased in the lung vasculature of patients with PAH and in the experimental animal model [33]. In vitro, Gal-3 treatment activated Jagged 1/Notch1 pathway, leading to EndMT [33]. The activated Jagged 1/Notch1 pathway was also identified in the PMVECs of bleomycin-induced PF rats [73]. Jagged1 knockdown resulted in the downregulation of SMAα and NF-κB expression in bleomycin-treated rat PMVECs [73]. In addition, expressions of SMAα and Jagged 1/Notch1 were positively correlated [73].

NF-κB signaling is known to play a critical role in EndMT [51]. NF-κB transcriptionally regulates Snail, which is a transcription factor for promoting EndMT [51]. Several groups have shown the activation of NF-κB-Snail signaling in TGFβ1-induced ECs and MCT-rat models [51,75]. In addition, the NOD1 agonist, g-dglutamyl-meso-diaminopimelic acid (iE-DAP), induces EndMT via Akt/NF-κB signaling [76]. Taken together, Jagged 1/Notch signaling and NF-κB signaling are vital during EndMT.

MicroRNAs (miRNAs) are 22-nucleotide, small, non-coding RNAs and important regulators of EndMT in many diseases [77,78]. It has been demonstrated that miRNAs, such as miR-21, miR-27a, miR-126a-5p, miR-130a, miR-139-5p, and miR-199a-5p, are involved in EndMT in vitro and in vivo. Parikh et al. used a network-based bioinformatic method to identify PH-modifying miRNAs and found that miR-21 is upregulated in the pulmonary vessels of PH animal models and human PAH patients [79]. In PAECs, hypoxia, inflammation, and BMPR2-dependent signaling induced miR-21 and suppressed its target, RhoB [79]. Another group provided evidence that miR-21 levels, Akt phosphorylation/activation, Snail expression, and NF-κB signaling were elevated in TGFβ1-induced EndMT [75]. Our group determined that iE-DAP downregulates miR-139-5p and activates Akt/NF-κB signaling, which leads to EndMT [76]. In addition, the overexpression of miR-139-5p reversed the nuclear translocation of NF-κB, resulting in the inhibition of iE-DAP-induced EndMT [76]. Li et al. reported that the mouse lung tissue of MCT-induced PH showed increased miR-130a expression, and its regulation was NF-κB-dependent [80]. Moreover, the overexpression of miR-130a induced EndMT in PMVECs [80]. Further, a lung tissue microarray identified that miR-126a-5p is upregulated in a neonatal PH rat model [81]. Hypoxia induced the expression of miR-126a-5p and led to EndMT through PI3K/Akt signaling in primary cultured rat PMVECs [81]. Furthermore, circulating miR-126a-5p levels were increased in the sera of PAH patients [81]. Several studies have reported that miR-27a is increased in pulmonary arteries of PAH. [26,82]. Moreover, there is upregulation of miR-27a in pulmonary arteries of PAH rats and hypoxia-induced PAECs [26]. MiR-27a acts as an EndMT inducer through the suppression of Smad5 and the upregulation of Snail and Twist [26]. In addition, the contribution of Snail-induced miR-199a-5p to radiation-induced EndMT has been evaluated previously [83].

In conclusion, many studies have demonstrated the interplay of various signaling pathways in the process of EndMT (Figure 2). However, better knowledge of how they engage in crosstalk with one another and what other mediators are involved is required for developing therapeutic strategies.
Figure 2. Molecular signaling pathways involved in endothelial-to-mesenchymal transition (EndMT). Stimulation with transforming growth factor-β (TGFβ), bone morphogenic protein (BMP), Notch ligands, inflammatory stress, and hypoxia induce expression of transcription factors, such as Twist1, Slug, and Snail, resulting in EndMT. During this process, mediators including microRNAs (miRNAs), Smad, Akt/nuclear factor kappa B (NF-κB), and hypoxia-inducible factor (HIF) play important roles in EndMT.

5. Targeting EndMT for Potential Therapeutic Applications

Many studies have reported potential therapeutic strategies to alleviate PF and PAH by targeting EndMT [7,33,34,41,52]. Adenoviral BMPR2 administration inhibited vascular remodeling and improved cardiac function in chronic hypoxia or MCT-induced PH rats [36]. In addition, recombinant BMP2 or BMP7 treatment reversed TGFβ1-induced EndMT in PMVECs [36]. One study suggested that modulating miRNAs may be a therapeutic strategy for PAH. When the MCT-exposed rats were infected with lentivirus-overexpressing miR-181b, RVSP, mean PAP, the decrease in pulmonary arterial wall thickness and the overexpression of miR-181b inhibited EndMT in rat PAECs by negatively regulating endocan and TGFβR1 [29]. Our group demonstrated that ginsenoside Rg3 attenuates iE-DAP-induced EndMT by upregulating miR-139-5p [76]. Nintedanib, a tyrosine kinase inhibitor, significantly decreased the phosphorylation of platelet-derived growth factor and fibroblast growth...
factor receptors, which were increased in the pulmonary artery of PAH, resulting in the improvement of PAH in vivo [34]. In addition, nintedanib downregulated the expression of mesenchymal markers in PMVECs [34]. One study suggested that hydrogen sulfide inhibits the NF-κB-Snail pathway and EndMT, resulting in a therapeutic effect on PAH [51]. In addition, treatment with the prostaglandin E2 receptor 4 (EP4) agonist decreases EndMT in vitro and reduces right ventricular fibrosis in a rat model of PAH [64]. The expression of Gal-3 was increased in PAH patients and a hypoxia-induced PAH rat model, and treatment with Gal-3 inhibitor, N-Lac, recovered RVSP, pulmonary artery acceleration, and pulmonary arterial velocity time integral [33]. Salvianolic acid A restores pulmonary vascular remodeling and improves vascular relaxation by upregulating Nrf2/HO-1 signaling while reducing TGFβ1 and EndMT in MCT-induced PAH rat models [35]. CD44v binds to and stabilizes the cystine transporter subunit (x-CT) when PAECs undergo EndMT. Sulfasalazine inhibits x-CT and restores EndMT in vitro and in vivo [32]. Rapamycin increased the expression of p120-catenin, a cytoplasmic scaffold protein that regulates cell-to-cell adhesion by binding VE-cadherin, and led to the downregulation of Twist1 expression in the lungs of MCT-induced PH rats [7]. Moreover, rapamycin inhibited the migration and proliferation of PAECs isolated from normal and PAH patients [7]. As such, rapamycin has curative effects on EndMT in MCT-induced PH rat models [7].

CD26/dipeptidyl peptidase 4 (DPP-4) is widely distributed in various cell types of the lung and promotes TGFβ signaling and EndMT [44,84]. Vildagliptin, a DPP-4 inhibitor, inhibits LPS-induced EndMT in PMVECs and attenuates the LPS-induced PF mouse model [44]. Another study confirmed that treatment with a DPP-4 inhibitor, sitagliptin, reduces pulmonary arterial remodeling and alleviates EndMT in PH-induced rats [52]. In addition, treatment with atazanavir sulphate, an antiretroviral protease inhibitor, ameliorates EndMT in cobalt chloride (CoCl2)-induced hypoxic PMVECs and decreases fibrotic lesions in a bleomycin-induced rat PF model, suggesting a potential therapeutic effect of atazanavir sulphate on EndMT [43]. Further, the overexpression of HSPB1, which protects against cellular stress, decreased radiation-induced EndMT in vitro and in vivo [45]. The HIF-1α inhibitor reduced the expression of HIF-1α, the phosphorylation of Smad2/3, and EndMT in radiation-induced PAECs; furthermore, it decreased the SMAα+ CD31+ double-positive cells and fibrosis area in the lungs of the RIPF mouse model [41].

Taken together, EndMT plays a critical part in vascular diseases, especially PF and PAH, and many studies on various therapeutic strategies targeting EndMT have been conducted by modulating various signaling pathways and epigenetic factors (Figure 3). However, further studies are still necessary to clarify the mechanism between EndMT and pulmonary vascular diseases to find more effective therapeutic agents that can treat vascular diseases, such as PF or PAH, by targeting EndMT. Tables 1 and 2 each list a summary of studies on EndMT in lung diseases and targeting EndMT as a therapeutic strategy.
Figure 3. The novel therapeutic approach for lung diseases by targeting EndMT. The modulation of signaling pathways involved in EndMT by miRNAs, inhibitors, and agonists has therapeutic effects in vitro and in vivo. Targeting EndMT reduces mesenchymal marker expression and pulmonary vascular remodeling, which ultimately ameliorates the hemodynamic phenotypes in the animal model of PH. In addition, the inhibition of EndMT decreases fibrotic lesion in various PF animal models. This provides insight into the therapeutic potential of targeting EndMT.
Table 1. Summary of the main studies on EndMT in lung diseases.

| Lung Diseases | In Vivo Model | In Vitro Model | Cell Line | Endothelial Markers | Mesenchymal Markers | EndMT Mediators | Reference |
|---------------|---------------|----------------|-----------|---------------------|---------------------|-----------------|-----------|
| PH            | SuHx, MCT rats | BMPR2 deficiency | PAECs     | CD31, VE-cad, CD34, Tie2 | SMAα, Vimentin, p-Vimentin | Twist1        | [7]       |
| PH            | BMPR2 KO mice | BMPR2 deficiency | EAhy926   | VE-cad              | N-cad               | Slug, Twist    | [11]      |
| PH            | EC-specific BMPR2 KO mice | BMPR2 deficiency | PAECs     | vWF, CD31, VE-cad | SM2α, SMAα, p-Vimentin | HMGA1, Snail, Slug | [23] |
| PH            | Hypoxia-exposed rats | Hypoxia | PAECs | vWF, CD31, VE-cad, Occudin | SMAα, Collagen I, III | HIF-1α, Twist1 | [27] |
| PH            | SuHx mice | Combination of TGFβ1, TNFα, and IL-1β | PAECs | vWF, CD31, VE-cad, Tic2 | SMAα, Calponin, Collagen I | Inflammatory cytokines | [30] |
| PH            | VE-cad Cre or Tie2 Cre-mTomato/mGFP lineage tracing mice | Hypoxia, TGFβ1 | PVEC | CD31, VE-cad | SM2α, Vimentin, FN, SMAα, FSP1 | HIF-2α, Snail, Slug, PHD2 | [50] |
| PH            | MCT rats, EC-specific phd2, egln1, KO mice | Hypoxia, TGFβ1 | PVEC | CD31, VE-cad | SMAα, Vimentin, FSP1, Collagen, MMP9 | TGFβ-RI, Smad2/3, HIF-1α, Snail | [41] |
| PF            | Radiation-exposed mice | Radiation | PAECs, PMVEC | CD31, VE-cad | SMAα, FN, Collagen I | Not determined | [42] |
| PF            | Bleomycin-treated Tie2-Cre/ CAG-CAT-Lac mice | Combination of Ras and TGFβ | MS-1 | CD31, VE-cad, CD34, Tie2 | SMAα, FN, Collagen I | Not determined | [42] |
| PF            | Radiation-exposed mice | HSPB1 deficiency | PAECs, PMVEC | CD31, VE-cad | SMAα | Inflammatory cytokines | [45] |

PH, pulmonary hypertension; PF, pulmonary fibrosis; SuHx, SU-5416/hypoxia model; MCT, monocrotaline; BMPR2, bone morphogenic protein receptor-2; KO, knockout; EC, endothelial cell; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor alpha; IL-1β, interleukin-1 beta; PHD2, prolyl hydroxylase domain protein 2; HSPB1, endothelial heat shock protein beta 1; PAECs, pulmonary arterial endothelial cells; PVECs, pulmonary vascular endothelial cells; PMVECs, pulmonary microvascular endothelial cells; MS-1, mouse microvascular endothelial cell line; CD31, cluster of differentiation 31; CD34, cluster of differentiation 34; VE-cad, vascular endothelial cadherin; vWF, von willebrand factor; SMAα, α-smooth muscle actin; N-cad, neural cadherin; SM2α, smooth muscle protein 22-α; FN, fibronectin; FSP1, fibroblast-specific protein 1; MMP, matrix metalloproteinase 9; HIF, hypoxia-inducible factor; HMGA1, high-mobility group AT-hook 1; p-Vimentin, phosphorylated vimentin.
### Table 2. Key studies targeting EndMT as a therapeutic strategy in PH and PF.

| Clinical Relevance | In Vitro Model                  | In Vivo Model             | Negative Regulator of EndMT | Reference |
|--------------------|-------------------------------|---------------------------|-----------------------------|-----------|
| PH                 | Combination of TGFβ1, TNFα, and IL-1β-treated rat PAECs | MCT rat                   | Rapamycin                   | [7]       |
| PH                 | Combination of TGFβ1, TNFα, and IL-1β-treated PAECs | SuHx mice                 | Sulfasalazine               | [32]      |
| PH                 | Combination of TGFβ2, TNFα, and IL-1β-treated PAECs | Hypoxia-exposed rat       | Galectin-3 inhibitor        | [33]      |
| PH                 | TGFβ1-treated PAECs           | MCT rat                   | Salvianolic acid A          | [35]      |
| PH                 | TGFβ1-treated PAECs           | MCT rat                   | Hydrogen sulfide           | [51]      |
| PH                 | TGFβ1-treated HUVECs          | MCT rat, Hypoxia-exposed rat | BMPR2, rhBMP2, rhBMP7     | [36]      |
| PF                 | Radiation-exposed PAECs       | Radiation-exposed mice    | HIF-1α inhibitor            | [41]      |
| PF                 | CoCl2-treated PMVECs          | LPS-treated PMVECs        | Atazanavir sulphate         | [43]      |
| PF                 | LPS-treated PMVECs            | Radiation-exposed EC      | Vildagliptin                | [44]      |
| PF                 | Radiation-exposed PMVECs      | Radiation-exposed EC      | HSPB1                       | [45]      |

PH, pulmonary hypertension; PF, pulmonary fibrosis; SuHx, SU-5416/hypoxia model; MCT, monocrotaline; EC, endothelial cell; LPS, lipopolysaccharides; CoCl2, cobalt chloride; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor alpha; IL-1β, interleukin beta; HSPB1, heat shock protein beta 1; HIF1α, hypoxia-inducible factor 1 alpha; BMPR2, bone morphogenetic protein receptor-2; rhBMP, recombinant human bone morphogenetic protein; EP4, prostaglandin E2 receptor 4; PAECs, pulmonary arterial endothelial cells; PMVECs, pulmonary microvascular endothelial cells; HUVECs, human umbilical vein endothelial cells.

### 6. Conclusions and Perspective

Here, we review the role of EndMT and its downstream pathways, and the therapeutic implications of targeting EndMT for lung diseases. As described earlier, many studies have demonstrated that EndMT is associated with the pathogenesis of PAH and PF in both in vitro and in vivo models, as well as in the lung tissue of humans. Thus, targeting EndMT can be a new therapeutic approach to treating lung diseases given the fact that there are no drugs to cure PAH or PF. Indeed, emerging evidence suggests that pharmacological approaches to inhibiting EndMT have the potential to treat lung diseases in vitro and in vivo. EndMT can also contribute to other human diseases, such as cancer, atherosclerosis, neointima formation, vascular calcification, and cerebral cavernous malformations. Therefore, inhibiting EndMT might represent a broadly applicable therapeutic strategy for the treatment of not only pulmonary vascular diseases, but also many diseases associated with endothelial dysfunction.

Although it is now clear that EndMT is closely associated with the pathogenesis of multiple diseases, the EndMT-targeting therapeutic approach needs to be carefully evaluated before clinical application. Given that ECs display organ-specific heterogeneity in function and phenotype, in health and disease, and in their response to environmental stimuli, it is possible that certain vessel types and vascular beds are more sensitive to EndMT-inducing signals. Therefore, it is important to understand the exact molecular mechanisms related to the EndMT process in the context of the heterogeneity of ECs. Importantly, EndMT may be a reversible biological process, what is called mesenchymal-to-endothelial transition, suggesting that exploration of the regulatory mechanism of the reversible process of EndMT will provide new insights into the prevention and treatment of various human diseases, and may be applied to tissue engineering. In conclusion, we believe that studies of EndMT in the context of endothelial heterogeneity will provide us with better insights into the molecular mechanisms of a broad variety of human diseases, and will help to develop novel vascular bed-specific therapies.

**Author Contributions:** Conceptualization, J.K., A.L., E.Y.; investigation, J.K., A.L., E.Y., Y.K.; writing-review and editing, J.K., A.L., E.Y.; visualization, Y.K., E.Y.; supervision, K.H.Y., K.I.K., M.-S.L. All authors have read and agreed to the published version of the manuscript.
**Funding:** This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the minister of Education, Science and Technology (NRF-2016R1A5A1011974 and NRF-2019R1A2C4069815 to J.K.).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Potenta, S.; Zeisberg, E.; Kalluri, R. The role of endothelial-to-mesenchymal transition in cancer progression. *Br. J. Cancer* **2008**, *99*, 1375–1379. [CrossRef] [PubMed]

2. Cho, J.G.; Lee, A.; Chang, W.; Lee, M.S.; Kim, J. Endothelial to mesenchymal transition represents a key link in the interaction between inflammation and endothelial dysfunction. *Front. Immunol.* **2018**, *9*, 294. [CrossRef]

3. Kim, S.M.; Huh, J.W.; Kim, E.Y.; Shin, M.K.; Park, J.E.; Kim, S.W.; Lee, W.; Choi, B.; Chang, E.J. Endothelial dysfunction induces atherosclerosis: Increased aggrecan expression promotes apoptosis in vascular smooth muscle cells. *BMB Rep.* **2019**, *52*, 145–150.

4. Sena, C.M.; Pereira, A.M.; Seica, R. Endothelial dysfunction—A major mediator of diabetic vascular disease. *Biochim. Biophys. Acta* **2013**, *1832*, 2216–2231. [CrossRef]

5. Krenning, G.; Barauna, V.G.; Krieger, J.E.; Harmsen, M.C.; Moonen, J.R. Endothelial plasticity: Shifting phenotypes through force feedback. *Stem Cells Int.* **2016**, *2016*, 9762959. [CrossRef]

6. Sabbineni, H.; Verma, A.; Somanath, P.R. Isoform-specific effects of transforming growth factor beta on endothelial-to-mesenchymal transition. *J. Cell. Physiol.* **2018**, *233*, 8418–8428. [CrossRef]

7. Ranchoux, B.; Antigny, F.; Rucker-Martin, C.; Hautefort, A.; Pechoux, C.; Boggaard, H.J.; Dorfmuller, P.; Remy, S.; LeWerf, F.; Plante, S.; et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. *Circulation* **2015**, *131*, 1006–1018. [CrossRef]

8. Ursoli Ferreira, F.; Eduardo Botelho Souza, L.; Hassibe Thome, C.; Tomazini Pinto, M.; Origassa, C.; Salustiano, S.; Marcel Faca, V.; Olsen Camara, N.; Kashima, S.; Tadeu Covas, D. Endothelial cells tissue-specific effects their responsiveness to TGF-beta2 during endothelial-to-mesenchymal transition. *Int. J. Mol. Sci.* **2019**, *20*, 458. [CrossRef]

9. Sanchez-Duffhues, G.; Garcia de Vinuesa, A.; Ten Dijke, P. Endothelial-to-mesenchymal transition in cardiovascular diseases: Developmental signaling pathways gone awry. *Dev. Dyn. Off. Publ. Am. Assoc. Anat.* **2018**, *247*, 492–508. [CrossRef]

10. Guan, S.; Zhou, J. CXCR7 attenuates the TGF-beta-induced endothelial-to-mesenchymal transition and pulmonary fibrosis. *Mol. Biosyst.* **2017**, *13*, 2116–2124. [CrossRef] [PubMed]

11. Hiepen, C.; Jatzlau, J.; Hildebrandt, S.; Kampfrath, B.; Goek, M.; Cuenca Camacho, J.L.; Haag, R.; Ruppert, C.; Sengel, G.; et al. BMPR2 acts as a gatekeeper to protect endothelial cells from increased TGFbeta responses and altered cell mechanics. *PloS Biol.* **2019**, *17*, e3000557. [CrossRef]

12. Zeisberg, E.M.; Tarnavski, O.; Zeisberg, M.; Dorfman, A.L.; McMullen, J.R.; Gustafsson, E.; Chandraker, A.; Yuan, X.; Pu, W.T.; Roberts, A.B.; et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. *Nature Med.* **2007**, *13*, 952–961. [CrossRef] [PubMed]

13. Thuan, D.T.B.; Zayed, H.; Eid, A.H.; Abou-Saleh, H.; Nasrallah, G.K.; Mangoni, A.A.; Pintus, G. A potential link between oxidative stress and endothelial-to-mesenchymal transition in systemic sclerosis. *Front. Immunol.* **2018**, *9*, 185. [CrossRef] [PubMed]

14. Simonneau, G.; Montani, D.; Celermajer, D.S.; Denton, C.P.; Gatzoulis, M.A.; Krowka, M.; Williams, P.G.; Souza, R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur. Respir. J.* **2019**, *53*. [CrossRef]

15. Kim, J.D.; Lee, A.; Choi, J.; Park, Y.; Kang, H.; Chang, W.; Lee, M.S.; Kim, J. Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension. *Exp. Mol. Med.* **2015**, *47*, e175. [CrossRef]

16. Lee, A.; McLean, D.; Choi, J.; Kang, H.; Chang, W.; Kim, J. Therapeutic implications of microRNAs in pulmonary arterial hypertension. *BMB Rep.* **2014**, *47*, 311–317. [CrossRef]

17. Roos-Hesselink, J.W.; Zijlstra, F. Pulmonary hypertension, how to diagnose and who to treat? *Neth. Heart J.* **2011**, *19*, 493–494. [CrossRef]

18. Lyle, M.A.; Davis, J.P.; Brozovich, F.V. Regulation of pulmonary vascular smooth muscle contractility in pulmonary arterial hypertension: Implications for therapy. *Front. Physiol.* **2017**, *8*. [CrossRef]
19. Pietra, G.G.; Edwards, W.D.; Kay, J.M.; Rich, S.; Kernis, J.; Schloo, B.; Ayres, S.M.; Bergofsky, E.H.; Brundage, B.H.; Dette, K.M.; et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, primary pulmonary hypertension registry. *Circulation* **1989**, *80*, 1198–1206. [CrossRef]

20. Rabinovitch, M. Molecular pathogenesis of pulmonary arterial hypertension. *J. Clin. Investig*. **2012**, *122*, 4306–4313. [CrossRef]

21. Ranchoux, B.; Harvey, L.D.; Ayon, R.J.; Babicheva, A.; Bonnet, S.; Chan, S.Y.; Yuan, J.X.; Perez, V.J. Endothelial dysfunction in pulmonary arterial hypertension: An evolving landscape (2017 Grover Conference Series). *Pulm. Circ.* **2018**, *8*. [CrossRef] [PubMed]

22. McLaughlin, V.V.; Archer, S.L.; Badesch, D.B.; Barst, R.J.; Farber, H.W.; Lindner, J.R.; Mathier, M.A.; McCoon, M.D.; Park, M.H.; Rosenson, R.S.; et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. *J. Am. Coll. Cardiol.* **2009**, *53*, 1573–1619. [CrossRef] [PubMed]

23. Hopper, R.K.; Moonen, J.R.A.J.; Diebold, I.; Cao, A.Q.; Rhodes, C.J.; Tojais, N.F.; Hennigs, J.K.; Gu, M.X.; Wang, L.L.; Rabinovitch, M. In pulmonary arterial hypertension, reduced BMPR2 promotes endothelial-to-mesenchymal transition via HMGA1 and its target slug. *Circulation* **2016**, *133*, 1783–1794. [CrossRef]

24. Gorelova, A.; Berman, M.; Al Ghouleh, I. Endothelial-to-mesenchymal transition in pulmonary arterial hypertension. *Antioxid. Redox Signal.* **2020**. [CrossRef]

25. Gaikwad, A.V.; Eapen, M.S.; McAlinden, K.D.; Chia, C.; Larby, J.; Myers, S.; Dey, S.; Haug, G.; Markos, J.; Glanville, A.R.; et al. Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis. *Expert Rev. Respir. Med.* **2020**, *14*, 1027–1043. [CrossRef] [PubMed]

26. Liu, T.; Zou, X.Z.; Huang, N.; Ge, X.Y.; Yao, M.Z.; Liu, H.; Zhang, Z.; Hu, C.P. MiR-27a promotes endothelial-mesenchymal transition in hypoxia-induced pulmonary arterial hypertension by suppressing BMP signaling. *Life Sci.* **2019**, *227*, 64–73. [CrossRef] [PubMed]

27. Zhang, B.; Niu, W.; Dong, H.Y.; Liu, M.L.; Luo, Y.; Li, Z.C. Hypoxia induces endothelial-mesenchymal transition in pulmonary vascular remodeling. *Int. J. Mol. Med.* **2018**, *42*, 270–278. [CrossRef] [PubMed]

28. Wang, J.; Yu, M.; Xu, J.; Cheng, Y.; Li, X.; Wei, G.; Wang, H.; Kong, H.; Xie, W. Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension. *J. Biomed. Sci.* **2019**, *26*, 6. [CrossRef] [PubMed]

29. Zhao, H.; Wang, Y.; Zhang, X.; Guo, Y.; Wang, X. miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1. *Toxicol. Appl. Pharmacol.* **2020**, *386*, 114827. [CrossRef] [PubMed]

30. Good, R.B.; Gilbane, A.J.; Trinder, S.L.; Denton, C.P.; Coghlan, G.; Abraham, D.J.; Holmes, A.M. Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. *Am. J. Pathol.* **2015**, *185*, 1850–1858. [CrossRef]

31. Shah, S.J. Pulmonary hypertension. *JAMA* **2012**, *308*, 1366–1374. [CrossRef]

32. Isobe, S.; Kataoka, M.; Endo, J.; Moriyama, H.; Okazaki, S.; Tsuchihashi, K.; Katsumata, Y.; Yamamoto, T.; Shirakawa, K.; Yoshida, N.; et al. Endothelial-mesenchymal transition drives expression of CD44 variant and xCT in pulmonary hypertension. *Am. J. Respir. Cell. Mol. Biol.* **2019**, *61*, 367–379. [CrossRef] [PubMed]

33. Zhang, L.; Li, Y.M.; Zeng, X.X.; Wang, X.Y.; Chen, S.K.; Gui, L.X.; Lin, M.J. Galectin-3-mediated transdifferentiation of pulmonary artery endothelial cells contributes to hypoxic pulmonary vascular remodeling. *Cell. Physiol. Biochem.* **2018**, *51*, 763–777. [CrossRef] [PubMed]

34. Tsutsumi, T.; Nagaoka, T.; Yoshida, T.; Wang, L.; Kuriyama, S.; Suzuki, Y.; Nagata, Y.; Harada, N.; Kodama, Y.; Takahashi, F.; et al. Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation. *PLoS ONE* **2019**, *14*, e0214697. [CrossRef] [PubMed]

35. Chen, Y.C.; Yuan, T.Y.; Zhang, H.F.; Yan, Y.; Wang, D.S.; Fang, L.H.; Lu, Y.; Du, G.H. Activation of Nrf2 attenuates pulmonary vascular remodeling via inhibiting endothelial-to-mesenchymal transition: An insight from a plant polyphenol. *Int. J. Biol. Sci.* **2017**, *13*, 1067–1081. [CrossRef]
36. Reynolds, A.M.; Holmes, M.D.; Danilov, S.M.; Reynolds, P.N. Targeted gene delivery of BMPR2 attenuates pulmonary hypertension. Eur. Respir. J. 2012, 39, 329–343. [CrossRef]

37. King, T.E., Jr.; Pardo, A.; Selman, M. Idiopathic pulmonary fibrosis. Lancet 2011, 378, 1949–1961. [CrossRef]

38. Richeldi, L.; Collard, H.R.; Jones, M.G. Idiopathic pulmonary fibrosis. Lancet 2017, 389, 1941–1952. [CrossRef]

39. Selman, M.; Pardo, A. Alveolar epithelial cell disintegration and subsequent activation a key process in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012, 186, 119–121. [CrossRef]

40. Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214, 199–210. [CrossRef]

41. Choi, S.H.; Hong, Z.Y.; Nam, J.K.; Lee, H.J.; Jang, J.; Yoo, R.J.; Lee, Y.J.; Lee, C.Y.; Kim, K.H.; Park, S.; et al. A hypoxia-induced vascular endothelial-to-mesenchymal transition in development of radiation-induced pulmonary fibrosis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015, 21, 3716–3726. [CrossRef] [PubMed]

42. Hashimoto, N.; Phan, S.H.; Imaizumi, K.; Matsuo, M.; Nakashima, H.; Kawabe, T.; Shimokata, K.; Hasegawa, Y. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am. J. Resp. Cell. Mol. 2010, 43, 161–172. [CrossRef] [PubMed]

43. Song, S.; Ji, Y.; Zhang, G.; Zhang, X.; Li, B.; Li, D.; Jiang, W. Protective effect of atazanavir sulphate against pulmonary fibrosis in vivo and in vitro. Basic Clin. Pharmacol. Toxicol. 2018, 122, 199–207. [CrossRef] [PubMed]

44. Suzuki, T.; Tada, Y.; Gladson, S.; Nishimura, R.; Shimomura, I.; Karasawa, S.; Matsuo, M.; Nakashima, H.; Kawabe, T.; Shimokata, K.; Hasegawa, Y. Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition. Respir. Res. 2017, 18, 177. [CrossRef]

45. Choi, S.H.; Nam, J.K.; Kim, B.Y.; Jang, J.; Jin, Y.B.; Lee, H.J.; Park, S.; Ji, Y.H.; Cho, J.; Lee, Y.J. HSPB1 inhibits the endothelial-to-mesenchymal transition to suppress pulmonary fibrosis and lung tumorigenesis. Cancer Res. 2016, 76, 1019–1030. [CrossRef]

46. Lu, X.; Gong, J.; Denney, P.A.; Yao, H. Endothelial-to-mesenchymal transition: Pathogenesis and therapeutic targets for chronic pulmonary and vascular diseases. Biochem. Pharm. 2019, 168, 100–107. [CrossRef]

47. Kim, J.; Kang, Y.; Kojima, Y.; Lighthouse, J.K.; Hu, X.; Aldred, M.A.; McLean, D.L.; Park, H.; Comhair, S.A.; Greif, D.M.; et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat. Med. 2013, 19, 74–82. [CrossRef]

48. Qiao, L.; Nishimura, T.; Shi, L.; Sessions, D.; Thrasher, A.; Trudell, J.R.; Berry, G.J.; Pearl, R.G.; Kao, P.N. Endothelial fate mapping in mice with pulmonary hypertension. Circulation 2014, 129, 692–703. [CrossRef]

49. Sakao, S.; Hao, H.; Tanabe, N.; Kasahara, Y.; Kurosu, K.; Tatsumi, K. Endothelial-like cells in chronic thromboembolic pulmonary hypertension: crosstalk with myofibroblast-like cells. Respir. Res. 2011, 12, 109. [CrossRef]

50. Tang, H.; Babicheva, A.; McDermott, K.M.; Gu, Y.; Ayon, R.J.; Song, S.; Wang, Z.; Gupta, A.; Zhou, T.; Sun, X.; et al. Endothelial HIF-2alpha contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition. Am. J. Physiol. Lung Cell Mol. Physiol. 2018, 314, L256–L275. [CrossRef]

51. Zhang, H.; Lin, Y.; Ma, Y.; Zhang, J.; Wang, C.; Zhang, H. Protective effect of hydrogen sulfide on monocrotalineinduced pulmonary arterial hypertension via inhibition of the endothelial mesenchymal transition. Int. J. Mol. Med. 2019. [CrossRef] [PubMed]

52. Xu, J.; Wang, J.J.; He, M.Y.; Han, H.H.; Xie, W.P.; Wang, H.; Kong, H. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Invest. 2018, 98, 1333–1346. [CrossRef] [PubMed]

53. Sabbinini, H.; Verma, A.; Artham, S.; Anderson, D.; Amaka, O.; Liu, F.; Narayanan, S.P.; Somanath, P.R. Pharmacological inhibition of beta-catatin prevents EndMT in vitro and vascular remodeling in vivo resulting from endothelial Akt1 suppression. Biochem. Pharmacol. 2019, 164, 205–215. [CrossRef] [PubMed]

54. Suzuki, T.; Carrier, E.J.; Talati, M.H.; Rathinasabapathy, A.; Chen, X.; Nishimura, R.; Tada, Y.; Tatsumi, K.; West, J. Isolation and characterization of endothelial-to-mesenchymal transition cells in pulmonary arterial hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 2018, 314, L118–L126. [CrossRef] [PubMed]

55. Nataraj, D.; Ernst, A.; Kalluri, R. Idiopathic Pulmonary Fibrosis is Associated with Endothelial to Mesenchymal Transition. Am. J. Resp. Cell Mol. 2010, 43, 129–130. [CrossRef] [PubMed]

56. Zhou, Y.; Li, P.; Duan, J.X.; Liu, T.; Guan, X.X.; Mei, W.X.; Liu, Y.P.; Sun, G.Y.; Wan, L.; Zhong, W.J.; et al. Aucubin Alleviates Bleomycin-Induced Pulmonary Fibrosis in a Mouse Model. Inflammation 2017, 40, 2062–2073. [CrossRef]
57. Mouratis, M.A.; Aidinis, V. Modeling pulmonary fibrosis with bleomycin. *Curr. Opin. Pulm. Med.* 2011, 17, 355–361. [CrossRef]

58. Singh, K.K.; Lovren, F.; Pan, Y.; Quan, A.; Ramadan, A.; Matkar, P.N.; Ehsan, M.; Sandhu, P.; Mantella, L.E.; Gupta, N.; et al. The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to-mesenchymal transition. *J. Biol. Chem.* 2015, 290, 2547–2559. [CrossRef]

59. Suzuki, T.; Tada, Y.; Nishimura, R.; Kawasaki, T.; Sekine, A.; Urushibara, T.; Kato, F.; Kinoshita, T.; Ikari, J.; West, J.; et al. Endothelial-to-mesenchymal transition in lipopolysaccharide-induced acute lung injury drives a progenitor cell-like phenotype. *Am. J. Physiol. Lung Cell Mol. Physiol.* 2016, 310, L1185–L1198. [CrossRef]

60. Groth, A.; Vrugt, B.; Brock, M.; Speich, R.; Ulrich, S.; Huber, L.C. Inflammatory cytokines in pulmonary hypertension. *Respir. Res.* 2014, 15, 47. [CrossRef]

61. Kovacic, J.C.; Dimmel, S.; Harvey, R.P.; Finkel, T.; Aikawa, E.; Krenning, G.; Baker, A.H. Endothelial to Mesenchymal Transition in Cardiovascular Disease: JACC State-of-the-Art Review. *J. Am. Coll. Cardiol.* 2019, 73, 190–209. [CrossRef]

62. Piera-Velazquez, S.; Jimenez, S.A. Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases. *Physiol. Rev.* 2019, 99, 1281–1324. [CrossRef]

63. Li, Z.; Wermuth, P.J.; Benn, B.S.; Lisanti, M.P.; Jimenez, S.A. Caveolin-1 deficiency induces spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro. *Am. J. Pathol.* 2013, 182, 325–331. [CrossRef] [PubMed]

64. Lai, Y.J.; Chen, I.C.; Li, H.H.; Huang, C.C. EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension. *Int. J. Mol. Sci.* 2018, 19, 727. [CrossRef] [PubMed]

65. Mammoto, T.; Muyleart, M.; Konduri, G.G.; Mammoto, A. Twist1 in Hypoxia-induced Pulmonary Hypertension through Transforming Growth Factor-beta-Smad Signaling. *Am. J. Respir. Cell Mol. Biol.* 2018, 58, 194–207. [CrossRef] [PubMed]

66. Morrell, N.W.; Aldred, M.A.; Chung, W.K.; Elliott, C.G.; Nichols, W.C.; Soubrier, F.; Trembath, R.C.; Loyd, J.E. Genetics and genomics of pulmonary arterial hypertension. *Eur. Respir. J.* 2019, 53. [CrossRef]

67. Kim, M.J.; Park, S.Y.; Chang, H.R.; Jung, E.Y.; Munkhjargal, A.; Lim, J.S.; Lee, M.S.; Kim, Y. Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2. *BMB Rep.* 2017, 50, 308–317. [CrossRef]

68. Mathew, R.; Huang, J.; Iacobas, S.; Iacobas, D.A. Pulmonary Hypertension Remodels the Genomic Fabrics of Major Functional Pathways. *Genes* 2020, 11, 126. [CrossRef]

69. Atkinson, C.; Stewart, S.; Upton, P.D.; Machado, R.; Thomson, J.R.; Trembath, R.C.; Morrell, N.W. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. *Circulation* 2002, 105, 1672–1678. [CrossRef]

70. Pinto, M.T.; Covas, D.T.; Kashima, S.; Rodrigues, C.O. Endothelial Mesenchymal Transition: Comparative Analysis of Different Induction Methods. *Biol. Proced. Online* 2016, 18, 10. [CrossRef]

71. Appelhoff, R.J.; Tian, Y.M.; Raval, R.R.; Turley, H.; Harris, A.L.; Pugh, C.W.; Ratcliffe, P.J.; Gleadle, J.M. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. *J. Biol. Chem.* 2004, 279, 38458–38465. [CrossRef]

72. Noseda, M.; McLean, G.; Niessen, K.; Chang, L.; Pollet, I.; Montpetit, R.; Shahidi, R.; Dorovini-Zis, K.; Li, L.; Beckstead, B.; et al. Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. *Circ. Res.* 2004, 94, 910–917. [CrossRef] [PubMed]

73. Yin, Q.; Wang, W.; Cui, G.; Yan, L.; Zhang, S. Potential role of the Jagged1/Notch1 signaling pathway in the endothelial-myofibroblast transition during BLM-induced pulmonary fibrosis. *J. Cell. Physiol.* 2018, 233, 2451–2463. [CrossRef] [PubMed]

74. Chang, A.C.; Fu, Y.; Garside, V.C.; Niessen, K.; Chang, L.; Fuller, M.; Setiadi, A.; Smrz, J.; Kyle, A.; Minchinton, A.; et al. Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase. *Dev. Cell* 2011, 21, 288–300. [CrossRef] [PubMed]

75. Guo, Y.; Li, P.; Bledsoe, G.; Yang, Z.R.; Chao, L.; Chao, J. Kallistatin inhibits TGF-beta-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. *Exp. Cell Res.* 2015, 337, 103–110. [CrossRef]
76. Lee, A.; Yun, E.; Chang, W.; Kim, J. Ginsenoside Rg3 protects against iE-DAP-induced endothelial-to-mesenchymal transition by regulating the miR-139-5p-NF-kappaB axis. *J. Ginseng Res.* 2020, 44, 300–307. [CrossRef]

77. Kim, J. MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology. *BMB Rep.* 2018, 51, 65–72. [CrossRef]

78. Salvi, V.; Gianello, V.; Tiberio, L.; Sozzani, S.; Bosisio, D. Cytokine Targeting by miRNAs in Autoimmune Diseases. *Front. Immunol.* 2019, 10, 15. [CrossRef]

79. Parikh, V.N.; Jin, R.C.; Rabello, S.; Gulbahce, N.; White, K.; Hale, A.; Cottrill, K.A.; Shaik, R.S.; Waxman, A.B.; Zhang, Y.Y.; et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. *Circulation* 2012, 125, 1520–1532. [CrossRef]

80. Li, L.; Kim, I.K.; Chiasson, V.; Chatterjee, P.; Gupta, S. NF-kappaB mediated miR-130a modulation in lung microvascular cell remodeling: Implication in pulmonary hypertension. *Exp. Cell Res.* 2017, 359, 235–242. [CrossRef]

81. Xu, Y.P.; He, Q.; Shen, Z.; Shu, X.L.; Wang, C.H.; Zhu, J.J.; Shi, L.P.; Du, L.Z. MiR-126a-5p is involved in the hypoxia-induced endothelial-to-mesenchymal transition of neonatal pulmonary hypertension. *Hypertens Res* 2017, 40, 552–561. [CrossRef] [PubMed]

82. Kang, B.Y.; Park, K.K.; Green, D.E.; Bijli, K.M.; Searles, C.D.; Sutliff, R.L.; Hart, C.M. Hypoxia mediates mutual repression between microRNA-27a and PPARgamma in the pulmonary vasculature. *PLoS ONE* 2013, 8, e79503. [CrossRef] [PubMed]

83. Yi, M.; Liu, B.; Tang, Y.; Li, F.; Qin, W.; Yuan, X. Irradiated Human Umbilical Vein Endothelial Cells Undergo Endothelial-Mesenchymal Transition via the Snail/miR-199a-5p Axis to Promote the Differentiation of Fibroblasts into Myofibroblasts. *BioMed Res. Int.* 2018, 2018, 4135806. [CrossRef] [PubMed]

84. Srivastava, S.P.; Goodwin, J.E.; Kanasaki, K.; Koya, D. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs. *Genes* 2020, 11, 211. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).